NASDAQ:CYCC Cyclacel Pharmaceuticals (CYCC) Stock Price, News & Analysis $2.67 -0.17 (-5.99%) (As of 12/29/2023 ET) Add Compare Share Share Today's Range$2.65▼$3.0650-Day Range$2.67▼$9.5052-Week Range$2.20▼$17.55Volume213,692 shsAverage Volume80,440 shsMarket Capitalization$2.24 millionP/E RatioN/ADividend YieldN/APrice Target$70.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Cyclacel Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside2,540.4% Upside$70.50 Price TargetShort InterestHealthy5.85% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.81Based on 6 Articles This WeekInsider TradingAcquiring Shares$26,334 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($26.25) to ($55.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.24 out of 5 stars 3.3 Analyst's Opinion Consensus RatingCyclacel Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $70.50, Cyclacel Pharmaceuticals has a forecasted upside of 2,540.4% from its current price of $2.67.Amount of Analyst CoverageCyclacel Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.85% of the float of Cyclacel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cyclacel Pharmaceuticals has recently decreased by 92.18%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCyclacel Pharmaceuticals does not currently pay a dividend.Dividend GrowthCyclacel Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CYCC. Previous Next 3.2 News and Social Media Coverage News SentimentCyclacel Pharmaceuticals has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Cyclacel Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest6 people have searched for CYCC on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat Follows5 people have added Cyclacel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cyclacel Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $26,334.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.47% of the stock of Cyclacel Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 16.33% of the stock of Cyclacel Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cyclacel Pharmaceuticals are expected to decrease in the coming year, from ($26.25) to ($55.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cyclacel Pharmaceuticals is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cyclacel Pharmaceuticals is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCyclacel Pharmaceuticals has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cyclacel Pharmaceuticals Stock (NASDAQ:CYCC)Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.Read More CYCC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYCC Stock News HeadlinesDecember 27, 2023 | americanbankingnews.comCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) CEO Spiro George Rombotis Buys 6,070 SharesDecember 26, 2023 | americanbankingnews.comCyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by StockNews.comDecember 31, 2023 | MarketBeat Internal (Ad)Claim Your $300 MarketBeat Account CreditClick the link below to claim your $300.00 account credit toward MarketBeat All Access. Pay just $99.00 for your 2024 MarketBeat All Access subscription (normally $399.00)December 22, 2023 | msn.comWhy Cyclacel Pharmaceuticals (CYCC) Shares Are Getting ObliteratedDecember 22, 2023 | finance.yahoo.comCyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq RulesDecember 22, 2023 | americanbankingnews.comBrookline Capital Management Weighs in on Cyclacel Pharmaceuticals, Inc.'s FY2023 Earnings (NASDAQ:CYCC)December 20, 2023 | msn.comBrookline Capital Downgrades Cyclacel Pharmaceuticals (CYCC)December 15, 2023 | benzinga.comCyclacel Pharmaceuticals Stock (NASDAQ:CYCC) Dividends: History, Yield and DatesDecember 31, 2023 | MarketBeat Internal (Ad)MarketBeat All Access New Year's Sale - Just $1.00Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Save 75% Your 2024 Subscription. Just $1.00 for the first 30 days.December 12, 2023 | finance.yahoo.comCyclacel Pharmaceuticals Announces Reverse Stock SplitNovember 30, 2023 | msn.comCyclacel Pharmaceuticals regains compliance with Nasdaq listing rulesNovember 28, 2023 | benzinga.comCyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-QNovember 28, 2023 | finance.yahoo.comCyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-QNovember 27, 2023 | msn.comCyclacel Pharmaceuticals (CYCC) Price Target Increased by 11.56% to 13.94November 24, 2023 | morningstar.comCyclacel Pharmaceuticals Inc CYCCOctober 19, 2023 | msn.comCyclacel Pharmaceuticals, Inc. PFD CONV EX 6% goes ex dividend tomorrowAugust 9, 2023 | msn.comCyclacel Pharmaceuticals GAAP EPS of -$0.44 beats by $0.06, revenue of $0.37MAugust 9, 2023 | finance.yahoo.comCyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business UpdateAugust 3, 2023 | finance.yahoo.comCyclacel Pharmaceuticals to Release Second Quarter 2023 Financial ResultsJuly 13, 2023 | finance.yahoo.comCyclacel Pharmaceuticals, Inc. (CYCC) Upgraded to Strong Buy: Here's WhyJune 15, 2023 | forbes.comJointown Pharmaceutical GroupMay 26, 2023 | msn.comOppenheimer Maintains Cyclacel Pharmaceuticals (CYCC) Outperform RecommendationMay 3, 2023 | finance.yahoo.comCyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax CreditMarch 8, 2023 | finance.yahoo.comCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2022 Earnings Call TranscriptMarch 7, 2023 | msn.comOppenheimer Maintains Outperform Rating for Cyclacel Pharmaceuticals: Here's What You Need To KnowMarch 3, 2023 | msn.comA Preview Of Cyclacel Pharmaceuticals's EarningsJanuary 30, 2023 | finance.yahoo.comCyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor ConferenceSee More Headlines Receive CYCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today12/31/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CYCC CUSIPN/A CIK1130166 Webwww.cyclacel.com Phone(908) 517-7330Fax866-271-3466Employees2,018Year FoundedN/APrice Target and Rating Average Stock Price Target$70.50 High Stock Price Target$120.00 Low Stock Price Target$21.00 Potential Upside/Downside+2,540.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($29.9850) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,200,000.00 Net MarginsN/A Pretax Margin-7,418.51% Return on Equity-278.92% Return on Assets-125.33% Debt Debt-to-Equity RatioN/A Current Ratio1.36 Quick Ratio1.36 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$19.06 per share Price / Book0.14Miscellaneous Outstanding Shares840,000Free Float772,000Market Cap$2.24 million OptionableNot Optionable Beta0.85 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Spiro George Rombotis (Age 64)President, CEO & Executive Director Comp: $763.55kMr. Paul McBarron (Age 62)Executive VP of Finance, CFO, COO, Secretary & Executive Director Comp: $394.68kDr. Mark H. Kirschbaum M.D. (Age 62)Senior VP & Chief Medical Officer Comp: $523.84kMs. Gill Christie (Age 66)Director of Human Resources Key CompetitorsAdial PharmaceuticalsNASDAQ:ADILNexImmuneNASDAQ:NEXISalarius PharmaceuticalsNASDAQ:SLRXFirst Wave BioPharmaNASDAQ:FWBIComera Life SciencesNASDAQ:CMRAView All CompetitorsInsidersSpiro George RombotisBought 6,070 shares on 12/21/2023Total: $20,091.70 ($3.31/share)Paul McbarronBought 1,886 shares on 12/21/2023Total: $6,242.66 ($3.31/share)View All Insider Transactions CYCC Stock Analysis - Frequently Asked Questions Should I buy or sell Cyclacel Pharmaceuticals stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CYCC shares. View CYCC analyst ratings or view top-rated stocks. What is Cyclacel Pharmaceuticals' stock price target for 2024? 3 Wall Street analysts have issued 12-month price targets for Cyclacel Pharmaceuticals' shares. Their CYCC share price targets range from $21.00 to $120.00. On average, they expect the company's stock price to reach $70.50 in the next twelve months. This suggests a possible upside of 2,540.4% from the stock's current price. View analysts price targets for CYCC or view top-rated stocks among Wall Street analysts. How have CYCC shares performed in 2023? Cyclacel Pharmaceuticals' stock was trading at $10.0050 at the start of the year. Since then, CYCC shares have decreased by 73.3% and is now trading at $2.67. View the best growth stocks for 2023 here. When is Cyclacel Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024. View our CYCC earnings forecast. How were Cyclacel Pharmaceuticals' earnings last quarter? Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) posted its earnings results on Monday, November, 13th. The biotechnology company reported ($7.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.70) by $1.65. The biotechnology company earned $0.02 million during the quarter. When did Cyclacel Pharmaceuticals' stock split? Cyclacel Pharmaceuticals's stock reverse split on the morning of Monday, December 18th 2023. The 1-15 reverse split was announced on Monday, December 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What is Spiro Rombotis' approval rating as Cyclacel Pharmaceuticals' CEO? 1 employees have rated Cyclacel Pharmaceuticals Chief Executive Officer Spiro Rombotis on Glassdoor.com. Spiro Rombotis has an approval rating of 100% among the company's employees. This puts Spiro Rombotis in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Cyclacel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Heat Biologics (HTBX), McEwen Mining (MUX) and Tesla (TSLA). How do I buy shares of Cyclacel Pharmaceuticals? Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CYCC) was last updated on 12/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.